This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
Study Type
OBSERVATIONAL
Enrollment
2
Dalbavancin 1500 mg intravenously x 1 dose
University of Colorado Hospital
Aurora, California, United States
Clinical cure
resolution of signs and symptoms (e.g. abdominal pain), bacterial eradication, reduction in clinical markers (e.g. peritoneal fluid findings, CRP, etc), and return of peritoneal dialysis functionality
Time frame: 14 days
Clinical cure
resolution of signs and symptoms (e.g. abdominal pain), bacterial eradication, reduction in clinical markers (e.g. peritoneal fluid findings, CRP, etc), and return of peritoneal dialysis functionality
Time frame: 28 days
Treatment emergent adverse events
Occurrence of any adverse events
Time frame: 14 days
Treatment emergent adverse events
Occurrence of any adverse events
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.